Track topics on Twitter Track topics that are important to you
Genmab will partner with Immatics Biotechnologies to discover and develop next-generation bispecific cancer immunotherapies through a collaboration that could generate more than $2.8 billion for Immatics, the companies said today. The companies have launched a research collaboration designed to combine Genmab's technologies and antibody expertise with Immatics' XPRESIDENT ® targets and T-cell receptor (TCR) capabilities. Immatics agreed to grant Genmab an exclusive license to three of its proprietary targets, with an option to license up to two additional targets at undisclosed predetermined payments. Under the companies’ exclusive license agreement, Genmab agreed to pay Immatics $54 million upfront and up to $550 million in payments tied to achieving development, regulatory and commercial milestones for each product—up to $2.75 billion if cancer immunotherapies based on all five targets are developed—as well as tiered royalties on net sales. Copenhagen-based Genmab has developed two next-generation antibody technologies - ...
Original Article: Genmab, Immatics Launch Up-to-$2.8B+ Cancer Immunotherapy PartnershipNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...